Krystal Biotech (KRYS) Accounts Payables (2016 - 2026)

Krystal Biotech has disclosed Accounts Payables across 11 years of filings, most recently posting $4.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.1 million, up 53.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (up 53.03% YoY), and the FY2025 annual result was $39.8 million, up 697.43% from the prior year.
• Accounts Payables came in at $4.1 million for Q1 2026 at Krystal Biotech, down from $39.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $53.1 million in Q3 2024 to a low of $2.1 million in Q3 2025.
• The 5-year median for Accounts Payables is $8.2 million (2022), against an average of $17.4 million.
• Across the five-year window, Accounts Payables jumped 1779.92% in 2022 and tumbled 96.05% in 2025, its largest moves.
• Krystal Biotech's Accounts Payables stood at $4.0 million in 2022, then soared by 440.34% to $21.5 million in 2023, then sank by 76.83% to $5.0 million in 2024, then jumped by 697.43% to $39.8 million in 2025, then sank by 89.71% to $4.1 million in 2026.
• The last three Accounts Payables figures came in at $4.1 million (Q1 2026), $39.8 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.